Lidco develops less-invasive heart monitor:
This article was originally published in Clinica
UK company Lidco has developed a less-invasive technology to provide continuous cardiac output data and direct measurement of left heart performance. The technology is a combination of indicator dilution and arterial pressure waveform analysis. Lidco will sell the system in the US through its sales organisation based in Florida, while Nissho and Sterimed will sell the technique in Japan and Europe respectively. The company believes that around 4 million people in the US would be suitable for the technology and estimates a world market potential of $500 million.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.